

NOVEL WAY OF CONSIDERING TEMPORAL REALIGNMENT

¹*Dr. Rafie Hamidpour Ph.D. D.E. DABFE, ²Dr. Soheila Hamidpour MD, ³Dr. Yasaman Hamidpour MD

*Corresponding Author: Dr. Rafie Hamidpour Ph.D. D.E. DABFE

DOI: <https://doi.org/10.5281/zenodo.23801089>

How to cite this Article: ¹*Dr. Rafie Hamidpour Ph.D. D.E. DABFE, ²Dr. Soheila Hamidpour MD, ³Dr. Yasaman Hamidpour MD. (2026). Novel Way of Considering Temporal Realignment. European Journal of Pharmaceutical and Medical Research, 13(11), 161–166.

This work is licensed under Creative Commons Attribution 4.0 International license.

Article Received on 30/09/2026

Article Revised on 21/10/2026

Article Published on 01/11/2026

ABSTRACT

Depending on your industry, "**Temporal Realignment**" refers to radically different cutting-edge breakthroughs. Because novel approaches have emerged simultaneously across several major fields, the framework can be analyzed through three primary lenses:

1. In AI & World Models: Temporal Straightening

In machine learning, a novel approach to temporal realignment is "**Temporal Straightening**". Historically, AI models aligned video frames or sequential actions using complex, computationally heavy explicit motion modeling or sequence-matching algorithms like Dynamic Time Warping (DTW).^[1,2,3,4]

- **The Novel Approach:** Instead of aligning data after the fact, researchers now use **curvature regularizes** during training. The AI calculates the vector trajectory between successive mental states (points A to B, and B to C) and actively forces the model to *minimize the angle* between them.^[1]
- **The Impact:** It flattens the AI's representation of time into straight trajectories, allowing robots and world models to predict the future with far less processing power and higher geometric clarity.^[1]

2. In Medicine & Clinical Data: Disease Progression Modeling (DPM-TR)

In healthcare and precision medicine, a classic problem is that chronic diseases (like Alzheimer's or macular degeneration) progress over decades, but clinical trials only track patients for short windows.^[1,2]

- **The Novel Approach: Disease Progression Modeling with Temporal Realignment (DPM-TR).** Using **hierarchical Bayesian algorithms**, researchers take fragmented, short-term data from thousands of patients who entered a study at different biological stages of a disease. The algorithm treats individual patient timelines as shifting variables, algorithmically shifting and re-aligning their "entry times" based on biomarker trajectories.^[1,2]
- **The Impact:** It synthetically reconstructs a seamless, multi-decade longitudinal timeline of a disease out of brief snapshots, allowing doctors to precisely pinpoint an individual's exact stage in a disease lifecycle.^[1,2]

3. In Gaming & Game Design: Passive Timeline Correction

If you are looking at temporal realignment from a creative or gaming mechanics perspective, **World of Warcraft** introduced a passive talent explicitly named **Temporal Realignment**.^[1,2]

- **The Novel Approach:** Rather than requiring highly skilled, active button-input to rewind time defensively (the classic *Alter Time* spell), this mechanic triggers automatically. When a player's health drops below 25%, their "past self" automatically corrects the current timeline, restoring health and position passively.
- **The Impact:** It bridges the gap between high-level macro play and casual play by automating chronological fail-safes.^[1,2]

KEYWORDS: Biostatistics, Chronic Disease Modeling & Medicine, Biology, Oncology and Chronotherapy.

BACKGROUND

Depending on your industry, "**Temporal Realignment**" refers to radically different cutting-edge breakthroughs. Because novel approaches have

emerged simultaneously across several major fields, the framework can be analyzed through three primary lenses.

Temporal Straightening

In machine learning, a novel approach to temporal realignment is "**Temporal Straightening**". Historically, AI models aligned video frames or sequential actions using complex, computationally heavy explicit motion modeling or sequence-matching algorithms like Dynamic Time Warping (DTW).

The Novel Approach: Instead of aligning data after the fact, researchers now use **curvature regularizers** during training. The AI calculates the vector trajectory between successive mental states (points A to B, and B to C) and actively forces the model to *minimize the angle* between them.^[1]

The Impact: It flattens the AI's representation of time into straight trajectories, allowing robots and world models to predict the future with far less processing power and higher geometric clarity.^[1]

Disease Progression Modeling (DPM-TR)

The Novel Approach: Disease Progression Modeling with Temporal Realignment (DPM-TR). Using **hierarchical Bayesian algorithms**, researchers take fragmented, short-term data from thousands of patients who entered a study at different biological stages of a disease. The algorithm treats individual patient timelines as shifting variables, algorithmically shifting and re-aligning their "entry times" based on biomarker trajectories.^[1,2]

The Impact: It synthetically reconstructs a seamless, multi-decade longitudinal timeline of a disease out of brief snapshots, allowing doctors to precisely pinpoint an individual's exact stage in a disease lifecycle.^[1,2]

Passive Timeline Correction

The Novel Approach: Rather than requiring highly skilled, active button-input to rewind time defensively (the classic Alter Time spell), this mechanic triggers automatically. When a player's health drops below 25%, their "past self" automatically corrects the current timeline, restoring health and position passively.

Counterarguments

While temporal realignment frameworks offer immense utility, critics, statisticians, and engineers raise significant **counterarguments** regarding their theoretical assumptions and practical execution.

The primary pushbacks are divided by domain

❖ In AI & World Models (Temporal Straightening)

While forcing an AI model to smooth out its internal timeline trajectory makes future planning computationally cheaper, critics emphasize structural flaws:^[1,2]

- **Elimination of Chaotic Realities:** By forcing the model to minimize trajectory curvature, the AI might ignore "highly non-linear, chaotic events" that are actually realistic (such as sudden turbulence in

robotics or sudden market crashes in finance).^[1,2]

- **The "Cheating" Latent Space Collapse:** Critics note that if the curvature regularizer is weighted too heavily during training, the AI will naturally find es into a single static representation, effectively erasing nuance to satisfy the mathematical constraint.^[1]
- **Misleading Optimization Goals:** Even if trajectories look straight, the mathematical landscape of the latent planning environment often remains highly non-convex. Gradient-based optimizers still get trapped in local minima, forcing engineers to rely on high-compute search methods anyway.^[1,2]

❖ 2. In Clinical Medicine & Biostatistics (DPM-TR)

Using models like Leaspy or SReFT to conceptually shift patient timelines face pushback from traditional epidemiologists:^[1, 2]

- **The Ergodic Fallacy:** These models rely on the assumption that a cross-sectional mix of many patients tracked briefly can be stitched together to accurately represent a single person's lifelong progression. Critics argue this ignores cohort effects (e.g., a 70-year-old patient's lifestyle and baseline health history are fundamentally different from a 40-year-old's).^[1, 2]
- **Deterministic Bias / Ignored Comorbidities:** Realignment models often assume a continuous, unidirectional timeline for a disease. In reality, a patient's progression can plateau, reverse temporarily, or accelerate due to a secondary disease (comorbidity). Forcing a timeline shift masks these distinct clinical phenotypes.^[1]
- **Lack of Regulatory & Practical Trust:** Because these shifted timelines are synthetic and mathematically imputed, regulatory bodies (like the FDA) remain highly skeptical. There is a large gap between demonstrating these models in research papers and trusting them to define clinical endpoints for real-world drug trials.^[1]

❖ 3. In Neuroscience (Neural Jitter Correction)

- **Signal Over-Smoothing:** Critics of slice-timing correction and event- warping argue that by mathematically shifting neural signals to align them, researchers risk scrubbing away the *actual* biological mechanism. The "temporal jitter" or lag in a human brain might not be noise; it might be how the brain dynamically codes attention or processes cognitive working memory. Shifting it out of existence treats vital biological variations as an error.^[1]

❖ 4. In Gaming & Design (Passive Alignment)

- **Skill Ceiling Flattening:** In game balance, critics of passive chronological fail-safes (like World of Warcraft's talent) argue that automating timeline

alignment removes mechanical depth. It lowers the gap between a highly skilled player who knows exactly when to manually rewind time and a casual player, making high-level mastery feel unrewarding.^[1]

CONCLUSIONS

Weighing the historical background against the major theoretical pushbacks leads to a definitive set of conclusions regarding **Temporal Realignment**.

Ultimately, temporal realignment marks a paradigm shift from a rigid, clock-based understanding of time toward an **intrinsic, state-based concept of progression**.

1. Paradigm Shift: Time is Variable, Progression is Constant

The overarching conclusion is that **chronological time is an imperfect proxy for systemic progression**. Whether analyzing a patient's biological markers, a robot's geometric trajectory, or a brain's neural spikes, clock time introduces artificial noise.

Temporal realignment successfully shifts the analytical focus from *when* an event happened to

where the system stands on its evolutionary path.

2. High Value with Hidden Mathematical Risks

While methodologies like **Disease Progression Modeling (DPM-TR)** or trajectory straightening solve the "fragmented data" and "computational intensity" problems, they introduce major statistical trade-offs. The primary risk is **over-smoothing**. By shifting data mathematically to force alignment, researchers risk treating meaningful, chaotic real-world variations (like clinical comorbidities or complex physical environments) as mere error noise.

3. The Future: Conditional & Hybrid Realignment

Moving forward, temporal realignment is evolving from a strict, mandatory data-warping tool into a conditional framework. To satisfy critics and regulatory bodies, modern pipelines are shifting toward **hybrid architectures**. These models realign macroscopic trajectories for overall predictability while actively preserving micro-temporal variances to capture chaos, anomalies, and individual biological differences.

Summary of Cross-Domain Conclusions			
Domain	Core Benefit	Primary Danger	Ultimate Verdict
Artificial Intelligence	Radical drop in computer processing; smoother, predictable future states.	Erasing real-world chaotic variations; latent space collapse.	Highly effective for macro planning, but needs safety overrides for sudden changes.
Biostatistics & Medicine	Seamlessly maps multi-decade disease lifecycles using short-term snapshots.	The Ergodic Fallacy; masking unique individual sub-types of diseases.	Revolutionary for research , but requires extensive validation before regulatory drug trial approval.
Neuroscience	Removes sensory/neural jitter to reveal interconnected network timing.	Artificially scrubbing away vital biological mechanisms coded as latency.	Essential for preprocessing , but must be balanced against intentional brain delay.

Summary Outlook

The **summary outlook** for temporal realignment reveals a technology moving rapidly out of theoretical mathematics and into high-stakes practical deployment. Across all fields, the core objective is shifting from *fixing* broken chronological data retroactively to *structuring* systems that inherently understand fluid, non-linear progression.

Conflict of Interest

Authors declare no conflict of interest.

REFERENCES

- Paz MP, *et al.* Rare diseases epidemiology research. In *RareDiseases Epidemiology*, 2010; 17–39.
- Jewell NP. Natural history of diseases: Statistical designs and issues. *Clin. Pharmacol. Ther.*, 2016; 100: 353–361. doi: 10.1002/cpt.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cook SF, Bies RR. Disease progression modeling: Key concepts and recent developments. *Curr. Pharmacol. Rep.*, 2016; 2: 221–230. doi: 10.1007/s40495-016-0066-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- The natural history of disease. *N. Engl. J. Med.*, 240: 442–235 443. <https://www.nejm.org/doi/full/10.1056/NEJM194903172401111> (1949).
- Shen LL, Sun M, Grossetta Nardini HK, Del Priore LV. Progression of unifocal vs. multifocal geographic atrophy in age-related macular degeneration: A systematic review and meta-analysis. *Ophthalmol. Retina*, 2020; 4: 899–910. doi: 10.1016/j.oret.2020.03.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shah AR, Del Priore LV. Progressive visual loss in subfoveal exudation in age-related macular degeneration: A meta-analysis using lineweaver-burke plots. *Am. J. Ophthalmol.*, 2007; 143: 83–89. doi: 10.1016/j.ajo.2006.09.043. [DOI] [PubMed] [Google Scholar]

7. Liu TYA, Shah AR, Del Priore LV. Progression of lesion size in untreated eyes with exudative age-related macular degeneration: A meta-analysis using lineweaver-burkplots. *JAMA Ophthalmol*, 2013; 131: 335–340. doi: 10.1001/jamaophthalmol.2013.818. [DOI] [PubMed] [Google Scholar]
8. Shen L, Liu F, Grossetta Nardini H, Del Priore LV. Natural history of geographic atrophy in untreated eyes with nonexudative age-related macular degeneration: A systematic review and meta-analysis. *Ophthalmol. Retina*. 2018; 2: 914–921. doi: 10.1016/j.oret.2018.01.019. [DOI] [PubMed] [Google Scholar]
9. Shen LL, Liu F, Grossetta Nardini HK, Del Priore LV. Fellow eye status is a biomarker for the progression rate of geographic atrophy: A systematic review and meta-analysis. *Ophthalmol. Retina*, 2019; 3: 305–315. doi: 10.1016/j.oret.2018.11.013. [DOI] [PubMed] [Google Scholar]
10. Shen LL, Liu F, Nardini HG, Del Priore LV. Reclassification of fundus autofluorescence patterns surrounding geographic atrophy based on progression rate: A systematic review and meta-analysis. *Retina*. 2019;39:1829–1839. doi: 10.1097/IAE.0000000000002480. [DOI] [PubMed] [Google Scholar]
11. Shen LL, Sun M, Khetsal S, Grossetta Nardini HK, Del Priore LV. Topographic variation of the growth rate of geographic atrophy in nonexudative age-related macular degeneration: A systematic review and meta-analysis. *Investig. Ophthalmol. Sci.*, 2020; 61: 2. doi: 10.1167/iovs.61.1.2. [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Shen, L. L. *et al.* Natural history of central sparing in geographic atrophy secondary to non-exudative age-related macular degeneration. *Br. J. Ophthalmol*, 2020; 1–7. [DOI] [PMC free article] [PubMed]
13. Shen LL, Sun M, Grossetta Nardini HK, Del Priore LV. Natural history of autosomal recessive stargardt disease in untreated eyes: A systematic review and meta-analysis of study- and individual-level data. *Ophthalmology*, 2019; 126: 1288–1296. doi: 10.1016/j.ophtha.2019.05.015. [DOI] [PubMed] [Google Scholar]
14. Shen LL, Ahluwalia A, Sun M, Young BK, Grossetta Nardini HK, Del Priore LV. Long-term natural history of atrophy in eyes with choroideremia—A systematic review and meta-analysis of individual-level data. *Ophthalmol. Retina*, 2020; 4: 840–852. doi: 10.1016/j.oret.2020.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
15. Shen LL, Ahluwalia A, Sun M, Young BK, Nardini HK, Del Priore LV. Long-term natural history of visual acuity in eyes with choroideremia: A systematic review and meta-analysis of data from 1004 individual eyes. *Br. J. Ophthalmol*, 2021; 105: 271. doi: 10.1136/bjophthalmol-2020-316028. [DOI] [PMC free article] [PubMed] [Google Scholar]
16. Yang E, et al. Quantifying the pathophysiological timeline of Alzheimer's disease. *299 J. Alzheimers Dis.*, 2011; 26: 745–753. doi: 10.3233/JAD-2011-110551. [DOI] [PubMed] [Google Scholar]
17. Vogl WD, Prosch H, Muller-Mang C, Schmidt-Erfurth U, Langs G. Longitudinal alignment of disease progression in fibrosing interstitial lung disease. *Med. Image Comput. Comput. Assist. Interv*, 2014; 17: 97–104. doi: 10.1007/978-3-319-10470-6_13. [DOI] [PubMed] [Google Scholar]
18. Schlanitz FG, et al. Drusen volume development over time and its relevance to the course of age-related macular degeneration. *Br. J. Ophthalmol*, 2017; 101: 198–203. doi: 10.1136/bjophthalmol-2016-308422. [DOI] [PMC free article] [PubMed] [Google Scholar]
19. Berro J, Pollard TD. Local and global analysis of endocytic patch dynamics in fission yeast using a new “temporal superresolution” realignment method. *Mol. Biol. Cell*. 2014; 25: 3501–3514. doi: 10.1091/mbc.E13-01-0004. [DOI] [PMC free article] [PubMed] [Google Scholar]
20. Shechtman E, Caspi Y, Irani M. Space-time super-resolution. *IEEE Trans. Pattern Anal. Mach. Intell*, 2005; 27: 531–545. doi: 10.1109/TPAMI.2005.85. [DOI] [PubMed] [Google Scholar]
21. Kuan WL, et al. Modelling the natural history of Huntington's disease progression. *J. Neurol. Neurosurg Psychiatry*, 2015; 86: 1143–1149. doi: 10.1136/jnnp-2014-
22. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. *J. R. Stat. Soc. Ser. B (Stat. Methodol.)*, 2002; 64: 583–639. [Google Scholar]
23. Thiele S, Pfau M, Larsen PP, Fleckenstein M, Holz FG, Schmitz-Valckenberg S. Multimodal imaging patterns for development of central atrophy secondary to age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.*, 2018; 59: AMD1. doi: 10.1167/iovs.17-23315. [DOI] [PubMed] [Google Scholar]
24. Rosenfeld PJ, et al. Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: A randomized clinical trial. *Ophthalmology*, 2018; 125: 1556–1567. doi: 10.1016/j.ophtha.2018.03.059. [DOI] [PubMed] [Google Scholar]
25. Wang J, Ying G-S. Growth rate of geographic atrophy secondary to age-related macular degeneration: A meta-analysis of natural history studies and implications for designing future trials. *Ophthalmic Res.*, 2021; 64(2): 205–215. doi: 10.1159/000510507. [DOI] [PubMed] [Google Scholar]
26. Yehoshua Z, et al. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. *Ophthalmology*, 2011; 118:

- 679–686. doi: 10.1016/j.opthta.2010.08.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
27. Keenan TD, et al. Progression of geographic atrophy in age-related macular degeneration: Areds2 report number 16. *Ophthalmology*, 2018; 125: 1913–1928. doi: 10.1016/j.opthta.2018.05.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
 28. Feuer WJ, et al. Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: A reanalysis of age-related eye disease study report no. 26. *JAMA, Ophthalmol*, 2013; 131: 110–111. doi: 10.1001/jamaophthalmol.2013.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
 29. Geweke JF. Evaluating the Accuracy of Sampling-based Approaches to the Calculation of Posterior Moments. Federal Reserve Bank of Minneapolis, 1991. [Google Scholar]
 30. Zuur A, Ieno EN, Walker N, Saveliev AA, Smith GM. *Mixed Effects Models and Extensions in Ecology with R*. Springer Science & Business Media; 2009. [Google Scholar]
 31. Rudnicka AR, et al. Incidence of late-stage age-related macular degeneration in American whites: Systematic review and meta-analysis. *Am. J. Ophthalmol*, 2015; 160: 85–93.e83. doi: 10.1016/j.ajo.2015.04.003. [DOI] [PubMed] [Google Scholar]
 32. Klein R, Chou C-F, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. *Arch. Ophthalmol*, 2011; 129: 75–80. doi: 10.1001/archophthalmol.2010.318. [DOI] [PubMed] [Google Scholar]
 33. Myers RH. Huntington's disease genetics. *NeuroRx*, 2004; 1: 255–262. doi: 10.1602/neurorx.1.2.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
 34. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden M, Group aIHsDC A new model for prediction of the age of onset and penetrance for Huntington's disease based on cag length. *Clin. Genet*, 2004; 65: 267–277. doi: 10.1111/j.1399-0004.2004.00241.x. [DOI] [PubMed] [Google Scholar]
 35. Eastman AE, et al. Resolving cell cycle speed in one snapshot with a live-cell fluorescent reporter. *Cell Rep*, 2020; 31: 107804. doi: 10.1016/j.celrep.2020.107804. [DOI] [PMC free article] [PubMed] [Google Scholar]
 36. Wong WL, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. *Lancet Glob. Health*, 2014; 2: e106–e116. doi: 10.1016/S2214-109X(13)70145-1. [DOI] [PubMed] [Google Scholar]
 37. Holz FG, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials. *JAMA Ophthalmol*, 2018; 136: 666–677. doi: 10.1001/jamaophthalmol.2018.1544. [DOI] [PMC free article] [PubMed] [Google Scholar]
 38. Liao DS, et al. Complement c3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: A randomized phase 2 trial. *Ophthalmology*, 2020; 127: 186–195. doi: 10.1016/j.opthta.2019.07.011. [DOI] [PubMed] [Google Scholar]
 39. Kim BJ, et al. Orally administered alpha lipoic acid as a treatment for geographic atrophy: A randomized clinical trial. *Ophthalmol. Retina*. 2020; 4(9): 889–898. doi: 10.1016/j.oret.2020.03.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
 40. Jaffe GJ, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-Related macular degeneration: A randomized pivotal phase 2/3 trial. *Ophthalmology*, 2021; 128(4): 576–586. doi: 10.1016/j.opthta.2020.08.027. [DOI] [PubMed] [Google Scholar]
 41. Shen LL, Sun M, Ahluwalia A, Young BK, Park MM, Del Priore LV. Geographic atrophy growth is strongly related to lesion perimeter: Unifying effects of lesion area, number, and circularity on growth. *Ophthalmol. Retina*. 2021; 5(9): 868–878. doi: 10.1016/j.oret.2020.12.002. [DOI] [PubMed] [Google Scholar]
 42. Joachim N, Mitchell P, Kifley A, Rochtchina E, Hong T, Wang JJ. Incidence and progression of geographic atrophy: Observations from a population-based cohort. *Ophthalmology*, 2013; 120: 2042–2050. doi: 10.1016/j.opthta.2013.03.029. [DOI] [PubMed] [Google Scholar]
 43. Shen LL, et al. Relationship of topographic distribution of geographic atrophy to visual acuity in nonexudative age-related macular degeneration. *Ophthalmol. Retina*, 2021; 5(8): 761–774. doi: 10.1016/j.oret.2020.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
 44. Age-Related Eye Disease Study Research Group The age-related eye disease study (AREDS): Design implications AREDS report no. 1. *Control Clin. Trials*, 1999; 20: 573–600. doi: 10.1016/s0197-2456(99)00031-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
 45. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins c and e, beta carotene, and zinc for age-related macular degeneration and vision loss: Areds Report no. 8. *Arch. Ophthalmol*, 2001; 119: 1417–1436. doi: 10.1001/archophth.119.10.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
 46. Mailman MD, et al. The ncbi dbgap database of genotypes and phenotypes. *Nat. Genet*. 2007; 39: 1181–1186. doi: 10.1038/ng1007-1181. [DOI]

- [PMC free article] [PubMed] [Google Scholar]
47. Rueden CT, et al. ImageJ 2: ImageJ for the next generation of scientific image data. *BMC Bioinform.* 2017; 18: 529. doi: 10.1186/s12859-017-1934-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
 48. Plummer, M., Stukalov, A. & Denwood, M. Package 'rjags'. (2019).
 49. Schmitz-Valckenberg S, et al. Natural history of geographic atrophy progression secondary to age-related macular degeneration (geographic atrophy progression study) *Ophthalmology*, 2016; 123: 361–368. doi: 10.1016/j.ophtha.2015.09.036. [DOI] [PubMed] [Google Scholar]
 50. Schmitz-Valckenberg S, et al. Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration. *Investig. Ophthalmol. Vis. Sci.*, 2011; 52: 7640–7646. doi: 10.1167/iovs.11-7457. [DOI] [PubMed] [Google Scholar]
 51. Sadda SR, Chakravarthy U, Birch DG, Staurengi G, Henry EC, Brittain C. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. *Retina*, 2016; 36: 1806–1822. doi: 10.1097/IAE.0000000000001283. [DOI] [PMC free article] [PubMed] [Google Scholar]